GLP-1 and metabolic receptor agonists

Compounds in this category

13 of 13 entries are published. Compounds without a published entry are listed without a link.

• SemaglutideSemaglutide is a synthetic, acylated analogue of human glucagon-like peptide-1 that acts as an agonist at a single receptor, GLP-1R. It is the active ingredient of approved pharmaceutical products, and that approval belongs to those finished products rather than to the chemical.
• TirzepatideTirzepatide (development code LY3298176) is a synthetic, fatty-acid-modified peptide that acts as an agonist at two receptors at once — the GIP receptor and the GLP-1 receptor. It is the active ingredient of approved pharmaceutical products, and that approval belongs to those finished products rather than to the chemical.
• RetatrutideRetatrutide (development code LY3437943) is an investigational synthetic peptide that acts as an agonist at three receptors at once — the GIP, GLP-1 and glucagon receptors. It is not approved by the FDA for any use.
• CagrilintideCagrilintide (development code NNC0174-0833) is an investigational lipidated analogue of the pancreatic hormone amylin, designed for a weekly interval. It acts at amylin receptors rather than at incretin receptors, and it is not approved by the FDA for any use.
• CagriSemaCagriSema is an investigational fixed-ratio combination of two separate peptides — the amylin analogue cagrilintide and the GLP-1 receptor agonist semaglutide — administered together once weekly. It is not a single molecule and has no identifiers of its own, and it is not approved by the FDA.
• SurvodutideSurvodutide (development code BI 456906) is an investigational synthetic acylated peptide that acts as an agonist at two receptors at once — the glucagon receptor and the GLP-1 receptor. It is not approved by the FDA for any use.
• MazdutideMazdutide is a synthetic acylated analogue of oxyntomodulin that acts as an agonist at two receptors — the GLP-1 receptor and the glucagon receptor. It is approved in China and has not been approved by the FDA for any use.
• PemvidutidePemvidutide (development code ALT-801) is an investigational synthetic peptide that acts as an agonist at two receptors — the GLP-1 receptor and the glucagon receptor — and has been studied principally in liver disease. It is not approved by the FDA for any use.
• EloralintideEloralintide (development code LY3841136) is an investigational synthetic analogue of amylin reported to act selectively at the amylin 1 receptor rather than across the calcitonin receptor family. It is not approved by the FDA for any use.
• LiraglutideLiraglutide is a synthetic, acylated analogue of human glucagon-like peptide-1 that acts as an agonist at a single receptor, GLP-1R. It is the active ingredient of approved pharmaceutical products, and that approval belongs to those finished products rather than to the chemical.
• DulaglutideDulaglutide is a recombinant fusion protein in which a modified GLP-1 analogue is joined to an immunoglobulin G4 Fc fragment, acting as an agonist at a single receptor, GLP-1R. It is the active ingredient of an approved pharmaceutical product, and that approval belongs to that finished product rather than to the substance.
• ExenatideExenatide is the synthetic form of exendin-4, a 39-residue peptide isolated from Gila monster venom that acts as an agonist at a single receptor, GLP-1R. It is the active ingredient of approved pharmaceutical products, and that approval belongs to those finished products rather than to the chemical.
• LixisenatideLixisenatide is a synthetic 44-residue peptide derived from exendin-4 by deleting one proline and appending six lysine residues, acting as an agonist at a single receptor, GLP-1R. It is the active ingredient of approved pharmaceutical products, and that approval belongs to those finished products rather than to the chemical.